| INTRODUCTION
Many children and adolescents that have poorly controlled type 1 diabetes are noncompliant with home blood glucose (BG) monitoring. The lack of glucose data prevents proper insulin dosing. Continuous glucose monitors (CGM) have been used extensively but to date are limited in improving glycemic control in children and adolescents, in part due to lack of consistent wear.
1,2 CGM provide interstitial glucose data but are only US Food and Drug Administration (FDA) approved to be used for evaluating glucose trendstherapeutic decisions are supposed to be based on fingerstick self-blood glucose monitoring (SBGM). This dual burden lessens the potential use of CGM in those patients not willing to perform SBGM regularly. Whether sensor glucose (SG) data generated via CGM and used in real-time (ie, without confirmatory fingerstick glucose) would be safe remains unknown. We therefore performed a pilot study to investigate whether using real-time SG data for treatment decisions would be safe in children and adolescents with poorly controlled type 1 diabetes in a controlled inpatient environment. • Absolute difference between YSI and SG was ≥100 mg/dL
| RESEARCH DESIGN AND METHODS
• The absolute difference between YSI and SG was more than the participant's insulin sensitivity factor (ISF) used for high glucose correction dose
• YSI and sensor trends were in opposite directions (ie, one indicated rising whereas the other indicated declining glucose levels) and SG values. Subject ID was used as the random variable. Pre-or postmeal, glucose type (YSI or SG), meal (dinner, snack, and breakfast), and two-way and three-way interactions of these three variables were used as fixed factors. In addition, the model was adjusted for sex and body mass index z-score. Furthermore, AUC 70-180 of YSI and SG were ordered and categorized at median to form ordinal groups. Kappa test was used to measure the agreement between two categorical variables. A sensitivity and specificity analysis was also performed of these two variables to test the consistency in the detection above or below median of these two variables. All tests were two tailed at the level of significance of 0.05. Statistical software SAS, version 9.3, and SPSS, version 22, were used for data analysis.
| Statistical analysis

| RESULTS
The clinical characteristics of the 10 participants (all Caucasian) who completed the study are shown in A total of 30 meal or snack insulin doses (carbohydrate dose with or without correction dose) were administered to the 10 subjects.
The use of YSI vs SG for dose calculations is described in Table 3 .
Eight of 23 high glucose corrections required YSI for dosing: six of these because the absolute difference between SG and YSI was > insulin sensitivity factor (ISF), and two were because the rate of Table 4 shows the differences between high glucose correction doses when calculated using SG vs YSI. Calculation differences are provided for when patients actually used SG for calculations (n = 15), when the correction dose calculation required YSI (n = 8), and all correction doses combined. The range of differences between the two calculations (SG dose minus YSI dose) was from −2 units (SG < YSI dose) to +1 unit (SG > YSI dose). There were only 2 of 23 correction doses where the difference was two units (all SG < YSI). In 91% of dose calculation comparisons, the difference between correction doses calculated using SG vs YSI was within one unit (Table 4) .
Twenty-six postmeal dose assessments of plasma (YSI) glucose changes were able to be made, after excluding four because less than 2 hours had passed before another meal bolus was given by the family.
Mean (AESE) pre-and postmeal YSI glucose were 163 AE 18 mg/dL A comparison of the YSI and SG for the five episodes of hypoglycemia is provided in Table 5 . There was no severe hypoglycemia, with no YSI glucose under 60 mg/dL for any of the subjects at any time during the study. There were no episodes of diabetic ketoacidosis. There was a strong linear relationship between AUC 70-180 of YSI and SG (Pearson r = 0.68, P = 0.03) and there was a strong agreement between AUC 70-180 of YSI and SG (ICC = 0.75, P = 0.03). There was a moderate to strong agreement between two ordinal variables of median-split of AUC 70-180 (k = 0.6, P = 0.06). Furthermore, the sensitivity and specificity to detect above or below median of one variable using the corresponding split of the other variable were both at 80%.
| CONCLUSIONS
Our pilot study demonstrated that using sensor data rather than fingerstick or reference glucoses in real-time for treatment decisions was fundamentally safe. High glucose correction and mealtime doses using SG data in a controlled hospital environment did not result in significant hyper-or hypoglycemia or dosing errors.
To the best of our knowledge, this is the first study directly assessing the safety of using real-time sensor data for treatment decisions. Outpatient use of real-time CGM has been described, assessing use and effectiveness of an algorithm developed by investigators and coordinators in the Diabetes Research in Children Network (DirecNet), but safety was not formally assessed. 3 In that 3-mo study, patients and families were taught an algorithm that provided guidelines on making insulin adjustments based on SG values, taking into account the direction and rate of change of the glucose concentrations. All other published studies of CGM are in accordance with FDA approval of the devices (ie, treatment decisions are based on fingerstick data, not sensor data).
The current FDA-approved use of CGM devices is for glucose trend pattern assessment and not using SG data for treatment decisions. This is because the accuracy of CGM sensors is less than that of home glucose meters, potentially leading to inaccurate and possibly unsafe dosing. However, published studies indicate that use of SBGM declines with time while on CGM, 4,5 suggesting patients are already using SG for treatment decisions despite the devices not being FDA-approved to do so. Furthermore, in the SWITCH trial, 6 the number of fingerstick blood sugars tests performed by study participants decreased while wearing a sensor (4.9 vs 5.5 per day; P < 0.001), yet there was improvement in diabetes control. Our pilot study did not suggest that using SG for treatment decisions results in significant treatment errors or dose miscalculations. In fact, the differences between doses using SG vs YSI for calculating high glucose corrections were minimal, and in all but 2 of 23 instances the difference was one unit or less, and never more than two units.
Missing or unnecessarily treating low BGs remains a possibility when using SG rather than fingerstick blood sugars, but there was minimal hypoglycemia in our study. A large number of high BG corrections in our patients required YSI for dose calculations (8 out of 23), and thus it appears that SG cannot frequently be used for treatment decisions. However, the aim of this study was not to assess how frequently SG could be used instead of YSI, but to assess whether problems occurred when using SG for dose calculations. The criteria established for using YSI instead of SG for calculations were somewhat arbitrary, and may not be applicable in real-world settings.
There are potential pitfalls with our study. First, it was short term, lasting <24 hours. Second, although the protocol tried to mimic the home environment with regard to how patients and families would make management decisions, with little intervention by CRC staff for insulin doses and treatment of low BGs, it was in an inpatient controlled setting, and thus results cannot necessarily be generalized for outpatient use. However, the safety of using SG data for treatment decisions needed to be established, and the hospital, under a controlled environment, is ideally suited for early studies designed to establish such safety. Also, the sample size is small, but appropriate in obtaining preliminary safety data. Data from this pilot study can be used to develop longer and larger inpatient and subsequent outpatient studies.
In summary, using real-time sensor data for treatment decisions in this study was safe, and may provide additional glucose data that can be used for treatment decisions in patients who perform SBGM too infrequently. Additional long-term, larger inpatient and outpatient studies are needed to confirm the safety and efficacy of this approach.
ACKNOWLEDGMENTS
CGM devices and supplies were provided by Medtronic, Inc.
(Northridge, California). This study was registered on ClinicalTrials.gov 
Funding information
This study was funded by NIH #RO3 HD067329-01A1 and Nemours
Research Programs.
Disclosure of interests
LAF has received research support from Medtronic (CGM devices and supplies). NM has received research support in the form of devices and grant support from Medtronic. EB, KE, and JH report no competing financial interests exist.
